Custom-Designed SNP Array Facilitates Japanese Genomic Studies
|
By LabMedica International staff writers Posted on 16 Sep 2015 |

Image: The \"Japonica Array\" contains 659,253 SNPs, including tag SNPs for imputation, SNPs of Y chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics (Photo courtesy of Tohoku Medical Megabank Organization).
Japanese genomic researchers have created a single nucleotide polymorphism (SNP) array optimized for studies on the Japanese population.
The so-called "Japonica Array" was designed by investigators at the Tohoku University Tohoku Medical Megabank Organization (Sendai, Japan). As source material, the investigators used the Tohoku Medical Megabank Organization's reference panel (referred to as the 1KJPN panel), which contains more than 20 million SNPs from whole-genome sequence data from 1070 Japanese individuals. The 1KJPN panel contains the largest number of haplotypes of Japanese ancestry to date.
Beginning with the 1KJPN panel, the investigators designed a novel custom-made SNP array, containing 659,253 SNPs, including tag SNPs for imputation, SNPs of Y- chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics.
The Japonica Array was found to provide better imputation performance for Japanese individuals than the existing commercially available SNP arrays. Imputation is an information science technique for estimating the genotype of several millions of unmeasured SNPs with a SNP array by combining it with a reference panel.
The genomic coverage of the Japonica Array was 96.9% for common SNPs; that is, almost all common SNPs were covered by this array. Furthermore, the coverage of low-frequency SNPs reached 67.2%, which was higher than those of other existing arrays.
The investigators confirmed the high quality genotyping performance of the Japonica array using the 288 samples from the 1KJPN reference panel. Results obtained from genotype screening with a high-throughput sequencer yielded an average call rate of 99.7% and an average concordance rate of 99.7%. Thus, the creation of custom-made SNP arrays based on a population-specific reference panel was shown to be a practical way to facilitate further association studies through genome-wide genotype imputations.
The study was published in the June 25, 2015, online edition of the Journal of Human Genetics.
Related Links:
Tohoku University Tohoku Medical Megabank Organization
The so-called "Japonica Array" was designed by investigators at the Tohoku University Tohoku Medical Megabank Organization (Sendai, Japan). As source material, the investigators used the Tohoku Medical Megabank Organization's reference panel (referred to as the 1KJPN panel), which contains more than 20 million SNPs from whole-genome sequence data from 1070 Japanese individuals. The 1KJPN panel contains the largest number of haplotypes of Japanese ancestry to date.
Beginning with the 1KJPN panel, the investigators designed a novel custom-made SNP array, containing 659,253 SNPs, including tag SNPs for imputation, SNPs of Y- chromosome and mitochondria, and SNPs related to previously reported genome-wide association studies and pharmacogenomics.
The Japonica Array was found to provide better imputation performance for Japanese individuals than the existing commercially available SNP arrays. Imputation is an information science technique for estimating the genotype of several millions of unmeasured SNPs with a SNP array by combining it with a reference panel.
The genomic coverage of the Japonica Array was 96.9% for common SNPs; that is, almost all common SNPs were covered by this array. Furthermore, the coverage of low-frequency SNPs reached 67.2%, which was higher than those of other existing arrays.
The investigators confirmed the high quality genotyping performance of the Japonica array using the 288 samples from the 1KJPN reference panel. Results obtained from genotype screening with a high-throughput sequencer yielded an average call rate of 99.7% and an average concordance rate of 99.7%. Thus, the creation of custom-made SNP arrays based on a population-specific reference panel was shown to be a practical way to facilitate further association studies through genome-wide genotype imputations.
The study was published in the June 25, 2015, online edition of the Journal of Human Genetics.
Related Links:
Tohoku University Tohoku Medical Megabank Organization
Latest BioResearch News
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
- Nanopore Method Captures RNA Folding at Single-Molecule Resolution
- Tumor Microenvironment Marker Linked to Worse Survival in Solid Tumors
- Hidden Immune Gene Defect May Explain Kaposi Sarcoma Susceptibility
- Genetic Markers May Help Predict Amputation Risk in Peripheral Artery Disease
- Gene Signature Shows Promise for Depression Biomarker Testing
- AI-Driven Tumor Profiling Initiative Targets Precision Therapy Development
- Researchers Map Protein and Glycosylation Across 15 Human Body Fluids
- Telomere Length Abnormalities Linked to Lymphoma Development
- Biomarker Signals Chemotherapy Resistance in Relapsed Small Cell Lung Cancer
- Inflammatory Gene Signature Links Metabolic Disease to Pancreatic Cancer Recurrence
Channels
Clinical Chemistry
view channel
Mass Spectrometry Metabolomics Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
Statistical Method Improves Detection of Low-Level Cancer DNA in Blood Samples
Blood-based assays are increasingly used to detect and monitor cancer, but many require relatively high fractions of circulating tumor DNA, limiting their utility when disease burden is low.... Read more
AI Tool Improves Accuracy of Cancer Liquid Biopsy for Therapy Selection
Liquid biopsy is increasingly used to guide targeted therapy by detecting tumor-derived mutations in blood, but distinguishing true tumor signals from background noise remains challenging.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more








